Hutch News

Hutch News

Stories tagged 'antibody responses'

Thai HIV vaccine trial follow-up studies offer possible explanation for HIV prevention success

Peter Gilbert and SCHARP researchers, HVTN Laboratory Program, part of worldwide effort to understand trial outcome, influence future HIV vaccine studies

April 9, 2012

Fred Hutchinson Cancer Research Center researchers played a key role in the discovery of important immune responses that may have protected some volunteers from HIV in the RV144 Thai trial, the first HIV vaccine trial to show modest effectiveness in preventing HIV infection. Results from extensive RV144 laboratory studies were published April 5 in the New England Journal of Medicine.

View story >

HIV 'superinfection' boosts immune response

Overbaugh, Cortez-led study shows women infected by two different HIV strains exhibit strong antibody response; findings may aid vaccine development

April 2, 2012 | By Kristen Woodward

Researchers at the Fred Hutchinson Cancer Research Center found that women who have been infected by two different strains of HIV from two different sexual partners-a condition known as HIV superinfection-have more potent antibody responses that block the replication of the virus compared to women who've only been infected once.

View story >

American Society for Microbiology lauds Blish

HIV research garners early career award

Sept. 20, 2010

The Fred Hutchinson Cancer Research Center’s Dr. Catherine Blish is the recipient of an Interscience Conference on Antimicrobial Agents and Chemotherapy Young Investigator Award from the American Society for Microbiology for her work elucidating the role of neutralizing antibodies in HIV transmission.

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.